Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Twist Bioscience Corp — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.65 (market cap $7.77B), while Twist Bioscience Corp trades at $157.47 (market cap $10.32B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days and Twist Bioscience Corp for 27 Days on average.
| PDBC | TWST | |
|---|---|---|
Market Cap | $7.77B | $10.32B |
Volume | 4,055,996 | 5,894,998 |
52-Week High | $20.10 | $205.00 |
52-Week Low | $13.16 | $25.45 |
Typical Hold Time | 56 Days | 27 Days |
Sector | — | Health |
Enterprise Value | — | $10.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDBC trades at $19.41, down 0.26% with neutral technical signals from moving averages and oscillators. The ETF has demonstrated strong performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodity strength amid geopolitical tensions. Recent institutional activity shows mixed sentiment with significant short interest growth of 215.4% in September offset by new institutional positions from firms like Arlington Capital and Advisortrust Partners.
The commodity ETF faces a complex outlook with potential upside from ongoing geopolitical tensions and defensive portfolio rotation, but risks include the sharp increase in short interest and commodity market volatility. Analyst sentiment remains cautiously optimistic given the fund's strong 2026 performance and defensive characteristics in uncertain markets.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
